Continuous Tart Cherry Juice Supplementation With Metabolic Syndrome Participants
- Conditions
- Insulin ResistanceMetabolic SyndromeHypertension
- Interventions
- Dietary Supplement: Montmorency Tart Cherry JuiceDietary Supplement: Placebo
- Registration Number
- NCT03619941
- Lead Sponsor
- University of Hertfordshire
- Brief Summary
The present study examined the effect of Montmorency tart cherry juice on functional and blood-based cardio-metabolic markers in humans with Metabolic Syndrome. Participants consumed Montmorency tart cherry juice or a placebo beverage continuously for 7 days in a randomised, crossover trial. Outcome variables were measured immediately prior to supplementation and post-supplementation. Furthermore, on the 7th day of supplementation outcome variables were measured pre- and up to 5 hours post-bolus. It was hypothesised that Montmorency tart cherry juice would improve cardio-metabolic markers, particularly fasting insulin and systolic blood pressure. Furthermore, the study aimed to identify the mechanism of action for any effects of Montmorency tart cherry juice on blood pressure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Meet 3 of 5 criteria for Metabolic Syndrome based on National Cholesterol Education Program-Adult Treatment Panel III guidelines:
- Waist Circumference: >102cm (men), >88cm (women)
- Fasting Serum Triglycerides: ≥1.69 mmol.L-1
- Fasting High Density Lipoprotein: <1.03 mmol.L-1 (men), <1.29 mmol.L-1 (women)
- Blood Pressure: ≥130 mmHg SBP or ≥85 mmHg DBP
- Fasting Plasma Glucose: ≥6.1 mmol.L-1
- Smokers
- Current or previous history of gastrointestinal, cardiovascular, hepatic or renal disease
- Currently diagnosed with diabetes or uncontrolled hypertension (≥160/100 mmHg)
- Allergy to fructose, maltodextrin or specific fruit products
- Currently taking medication (such as steroids, NSAIDs, antibiotics, antihypertensive, hypoglycaemic, lipid-lowering drugs)
- Currently using any nutritional or antioxidant supplement. Heavy alcohol consumption (>14 units per week).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Montmorency Tart Cherry Juice Montmorency Tart Cherry Juice - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Change in Fasting Insulin Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) Change in Systolic and Diastolic Blood Pressure Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) Change in Fasting Glucose Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) Change in Fasting Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL) Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour)
- Secondary Outcome Measures
Name Time Method Change in Cardiac Haemodynamics Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) Beat-by-beat cardiac output, stroke volume, heart rate, total peripheral resistance, mean arterial pressure will be measured
Change in Angiotensin Converting Enzyme Inhibition activity Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (1 hour, 3 hour, 5 hour) Change in 24-hour Ambulatory Blood Pressure Baseline, Post-Supplementation (7 days) Systolic, Diastolic and Pulse Pressure will be measured
Change in Pulse Wave Analysis Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour) Change in HOMA2-IR, HOMA%S and HOMA%B Baseline, Post-Supplementation (7 days) Homeostatic Model Assessment of Insulin Resistance, Sensitivity and Beta-cell function
Change in Resting Metabolic Rate Baseline, Post-Supplementation (7 days) and Acute Post-Bolus (30 minutes, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour)
Trial Locations
- Locations (1)
University of Hertfordshire
🇬🇧Hatfield, Hertfordshire, United Kingdom